TRIM21和OTUD6A调节了AKT K27相关的非典型的无处不在,以调节癌症化学抵抗
Qiwei Jiang1,2, Peipei Song3, Shuishen Zhang4
1Center of Lung Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. jiangqw6@mail.sysu.edu.cn.
Nature structural & molecular biology
|November 4, 2025
概括
E3 无素结合酶 TRIM21 通过通过 K27 无素化抑制 AKT 活性来抑制瘤,这一过程与 OTUD6A 相反. 针对这一TRIM21-OTUD6A轴提供了针对AKT驱动癌症的策略.
科学领域:
- 分子生物学分子生物学
- 癌症生物学 癌症生物学
- 在Ubiquitination信号传输.
背景情况:
- 在生理和病理过程中,位化是至关重要的.
- 不典型的AKT在瘤发生中的作用还不清楚.
- 在各种癌症中,AKT信号经常受到调节障碍.
研究的目的:
- 为了研究非典型的AKT无处不在的机制.
- 阐明TRIM21和OTUD6A在AKT调节和瘤发生中的作用.
- 探索针对癌症AKT通路的治疗策略.
主要方法:
- 通过TRIM21调解的K27连接链,研究了使用K27连接链的AKT泛化.
- 评估了duebiquitinase OTUD6A 的对抗作用.
- 使用KrasG12D驱动的肺癌小鼠模型和体内研究.
主要成果:
- 通过K27链接,TRIM21可在任何地方化AKT,抑制其激酶活性和膜局部化.
- OTUD6A对抗TRIM21介导的AKT抑制;S6K1酸化并使OTUD6A无活化.
- Otud6a缺乏减少了肺瘤发生;TRIM21诱导抑制了体内瘤的生长.
结论:
- 不典型的K27通过TRIM21微调AKT活动的普基化,作为瘤抑制剂.
- TRIM21-OTUD6A轴代表了AKT的一个新型监管机制.
- 针对TRIM21-OTUD6A轴是AKT驱动癌症的潜在治疗策略.
相关概念视频
Covalently Linked Protein Regulators
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein.
These groups modify specific amino acids in a protein.
Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...


